Protocol Overview
Dosing Protocol
Standard
1.6 mg
250 mcg
TA1 3x/wk + BPC daily
8-12 weeks
Acute Immune
250 mcg 2x
TA1 daily (7d) then 3x/wk + BPC 2x daily
Maintenance
TA1 2x/wk + BPC daily
Key principle: TA1 has a long biological duration of action (~7 days of immune modulation per dose), so 2-3x weekly dosing maintains consistent immune enhancement. BPC-157 benefits from daily dosing for sustained tissue repair signaling.
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Injection site redness (mild)
Mild flu-like symptoms during first week of TA1 (immune activation)
Fatigue during initial immune reconstitution
Both peptides have extensive safety profiles. TA1 is approved in 35+ countries with decades of clinical use.
Precautions
TA1: Avoid with organ transplant immunosuppression
TA1: Caution with autoimmune conditions (may enhance immune activity)
BPC-157: Theoretical concern with active cancer (angiogenesis)
Not recommended during pregnancy
Blood Work Recommendations
Immune Panel
CD4/CD8 ratio, NK cell count, total lymphocytes
Baseline, Week 6, Week 12
Inflammation
hs-CRP, ESR, IL-6, TNF-alpha
Liver Function
ALT, AST, GGT
Baseline, Week 12
General
CBC with differential, CMP
Related Tools & Resources
Related Resources